Business description: Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Number of employees: 97

Sales by Activity: Prometheus Biosciences, Inc.

Fiscal Period: December20182019202020212022

Therapeutics

- 1.12M 1.23M 3.13M 6.81M

Diagnostic Services

- 22.67M - - -
See all business segments

Geographical breakdown of sales: Prometheus Biosciences, Inc.

Fiscal Period: December20182019202020212022

United States

- 23.79M 1.23M 3.13M 6.81M
See all geographic segments

Managers: Prometheus Biosciences, Inc.

Director TitleAgeSince
Chief Executive Officer 62 2023-06-15
Chief Tech/Sci/R&D Officer 53 2020-08-31
Chief Tech/Sci/R&D Officer 51 2018-07-31
Corporate Officer/Principal - -
Corporate Officer/Principal - 2021-01-31
See PROMETHEUS BIOSCIENCES, INC. governance

Members of the board: Prometheus Biosciences, Inc.

Manager TitleAgeSince
Director/Board Member 62 2023-06-15
Director/Board Member - 2023-06-15
Composition of the Board of Directors

Company details: Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

126 East Lincoln Avenue

07065, Rahway

+

https://www.precisionibd.com/
address Prometheus Biosciences, Inc.(RXDX)

Other Biotechnology & Medical Research

Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-1.50%+3.75%+38.33%-3.02% 47.96B
-0.87%+3.37%-2.89%-15.36% 36.65B
-0.77%-0.06%+5.35%+24.92% 26.22B
-1.27%-2.82%-28.10%-27.88% 15.97B
-1.71%-0.99%+64.98%+74.02% 15.52B
-3.01%-17.30%-67.17%-79.66% 12.55B
-2.93%-1.01%+9.72%-29.43% 11.51B
-1.90%+1.42%+14.68%+106.42% 10.98B
+6.11%+20.16% - - 10.86B
Average -1.23%+1.11%+4.36%+6.25% 20.91B
Weighted average by Cap. -1.20%+1.72%+10.50%+2.71%
See all sector performances
  1. Stock Market
  2. Equities
  3. RXDX Stock
  4. Company Prometheus Biosciences, Inc.